# Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer

> **NCT00042978** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 55 (actual)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer
- Recurrent Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** oblimersen sodium
- **DRUG:** carboplatin
- **DRUG:** etoposide

## Key facts

- **NCT ID:** NCT00042978
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2005-05
- **Final completion:** —
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2013-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00042978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00042978, "Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00042978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*